ArticleCureus2025
Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Papillary Thyroid Carcinoma: A Retrospective Biomarker Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProgrammed cell death ligand 1 (PD-L1) expression is a well-established prerequisite for the use of immune checkpoint inhibitors and is increasingly recognized as a prognostic biomarker in various malignancies. However, its prognostic significance in thyroid cancer, particularly papillary thyroid carcinoma (PTC), remains largely unexplored and somewhat controversial, with findings to date being limited and inconsistent. The aim of this study was to evaluate PD-L1 expression in a well-characterized cohort of patients with PTC and assess its association with key clinicopathological features and clinical outcomes. MATERIALS AND
methodsThis retrospective, single-center cohort study included patients with histologically confirmed PTC who underwent thyroid surgery at the Korgialenio-Benakio Hellenic Red Cross Hospital of Athens in Greece between 2007 and 2018. Formalin-fixed, paraffin-embedded tumor samples were assessed for PD-L1 expression using immunohistochemistry and scored using the combined positive score (CPS), with CPS ≥10 indicating PD-L1 positivity. Clinicopathological data were collected through review of patients' medical records and postoperative histopathology reports, and associations with PD-L1 status were analyzed. Disease-free survival (DFS) and overall survival (OS) were also evaluated using Kaplan-Meier methods.
resultsAmong 81 patients with PTC included in this study (median age: 48 years, 61/81 (83%) patients being female), PD-L1 positivity (CPS ≥10) was observed in 37/81 (45.7%) patients. CPS ≥10 status was significantly associated with larger tumor size, higher pT stage (pT3-pT4, as per the 8th edition of the American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) classification), extrathyroidal extension, lymph node metastasis, and the presence of aggressive histologic variants. Coexisting Hashimoto's thyroiditis and higher rates of radioactive iodine therapy were also more common in the PD-L1-positive group. At a median follow-up of nine years, the overall recurrence rate was 8.6% (7/81 patients), with significantly higher recurrence and shorter DFS among patients with CPS ≥10. OS remained high across both groups.
conclusionsPD-L1 expression was present in nearly half of this real-world Greek PTC cohort and was associated with multiple adverse clinicopathological features and an increased risk of recurrence. These findings support the potential utility of PD-L1 as a prognostic biomarker in PTC and may inform postoperative risk stratification and follow-up strategies, although further prospective studies in larger, multicenter cohorts are warranted to corroborate these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.